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a b s t r a c t
The 2007US approval for use of AnnArbor strain live attenuated inﬂuenza vaccine (LAIV) in children aged
24 through 59months included precautions against use in (1) children <24months and children aged 24
through 59monthswith (2) asthma, (3) recurrentwheezing, and (4) altered immunocompetence. Results
from the third season (2009–2010) of a 3-year study postmarketing commitment to monitor LAIV vacci-
nation rates and frequency of hospitalizations or emergency department visits within 42 days after LAIVeywords:
sthma
heezing
hildren
mmunocompromised
ive attenuated inﬂuenza vaccine
are reported here. As in the ﬁrst 2 seasons, LAIV usage in cohorts 1, 2, and 4 were low relative to those
in LAIV-recommended populations. The only numerically increased risk observed was for respiratory
events in children aged <24 months administered LAIV, compared to those administered trivalent inac-
tivated inﬂuenza vaccine (TIV). The number of children vaccinated with LAIV was small and precluded
precise quantiﬁcation of rare event.
© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
rivalent inactivated inﬂuenza vaccine
. Introduction
In September 2007, Ann Arbor strain LAIVwas approved for use
n children 2 through 4 years of age with precautions against use
n children <24 months of age and children 24 through 59 months
f age with asthma, recurrent wheezing, or altered immunocom-
etence. Because data from a large randomized study showed an
ncreased risk ofmedically signiﬁcantwheezing in LAIV-vaccinated
hildren 6 through 23 months of age and an increased rate of hos-
italization in LAIV-vaccinated children 6 through 11 months of
ge [1], LAIV was not approved for use in children younger than 24
onths. MedImmune committed to the US Food and Drug Admin-
stration to conduct a 3-year study assessing the frequency of use
nd safety of LAIV in speciﬁc groups of children <5 years of agewho
re not recommended to receive LAIV.
The results from the ﬁrst 2 study seasons have been reported
y Tennis et al. in 2011 [2]. The current report describes the results
rom the third inﬂuenza vaccination season, 2009–2010. Among
he3monitored seasons, 2009–2010 includes the largestnumberof
hildren vaccinatedwith LAIV. Thismonitoring effort evaluated the
∗ Corresponding author. Tel.: +1 919 316 3812; fax: +1 919 541 7222.
E-mail address: ptennis@rti.org (P. Tennis).
264-410X © 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
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rate of LAIV vaccination and frequency of emergency department
(ED) visits or hospitalizations within 42 days postvaccination with
LAIV compared with that of trivalent inactivated inﬂuenza vac-
cine (TIV) among the nonrecommended pediatric populations. This
activity was designed tomonitor for previously unidentiﬁed safety
concerns rather than test speciﬁc hypotheses about increased risks
of speciﬁc conditions.
2. Methods
Detailed deﬁnitions are provided by Tennis et al. [2]. In brief,
4 cohorts of interest were ascertained among children younger
than 60 months who received LAIV or TIV during the study period
and enrolled in a health insurance plan with claims data captured
by MarketScan® Research Data (Thomson Reuters, New York, NY,
USA). Cohort 1 included all children <24months of age. The cohorts
aged 24 through 59 months of age were deﬁned as follows: cohort
2, with asthma (i.e. with an asthma diagnosis and treatment in the
previous 12 months), cohort 3, with recurrent wheezing (i.e. with
a relevant treatment occurring ≥1 time in the previous 12 months
but no asthma diagnosis), and cohort 4, with immunocompromise
(i.e. with a relevant diagnosis, use of glucocorticosteroids, or use
of immunosuppressivemedication). To provide context for the fre-
quency of use in the 24 through 59-month cohorts of interest, a
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eneral population cohort was created comprising children aged
4 through 59 months who  met  the enrollment criteria but did not
eet the inclusion criteria for the other cohorts.
All cohort members had to meet the eligible ages between
ugust 1, 2009, and February 17, 2010, and their cohort member-
hip status was based on available claims from August 1, 2008,
hrough February 17, 2010. Because children could move into a
ew age category and enter, leave, or change cohorts through-
ut the vaccination season, we used the number of relevant
accinations/child-days of follow-up to derive a vaccination rate
n each cohort. Vaccination rates were calculated by dividing the
umber of children vaccinated in a cohort by the total child-days
f follow-up within a cohort. Conﬁdence intervals were estimated
sing Episheet [3]. We  evaluated the severity of disease classiﬁ-
ation by characterizing utilization of medical services for each
ohort.
To assess the type and number of ED visits or hospitaliza-
ions occurring within 42 days postvaccination in each cohort, only
accinated children were followed. The vaccinated asthma and
ecurrent wheezing cohorts were combined for the safety analysis
ecause of the presumed similar pathophysiology in both cohorts.
o avoid confounding from vaccination for the 2009 H1N1 pan-
emic inﬂuenza strain, we excluded children who had a vaccination
or H1N1 on or within 42 days after seasonal inﬂuenza vaccination.
utcomes of interest were (1) in all cohorts, any unique ED visit or
ospitalization, (2) among children ≤24 months of age and those
ith asthma and recurrent wheezing, any ED visit or hospitalization
or speciﬁc lower respiratory conditions [4], and (3) among those
n the immunocompromised cohort, any ED visit or hospitalization
or an infectious disease.
.  Results
.1. Vaccination incidence
During  the 2009–2010 season, there were 666,599 total children
n cohort 1 (<6 months of age, 12%; 6 through 11 months, 20%; 12
hrough 17 months, 28%; and 18 through 23 months, 40%), 79,325
hildren in cohort 2 (24 through 59 months of age with asthma),
6,849 children in cohort 3 (24 through 59 months of age with
ecurrent wheezing), and 54,809 children in cohort 4 (24 through
9 months of age with immunocompromise). Among cohorts 1, 2,
 and 4, respectively, there were 775, 3457, 5821, and 361 children
accinated with LAIV (Table 1). The incidence ratio for vaccination
ith LAIV in nonrecommended populations compared with LAIV
accination in the general population ranged from 0.79 (95% CI,
.77–0.81) for cohort 3 to 0.012 (95% CI, 0.011–0.013) for cohort 1.
.2. Safety analysis
Among  the 686 cohort 1 children vaccinated with LAIV and with-
ut vaccination for the 2009 H1N1 pandemic strain concurrently
r during follow-up, there were few lower respiratory outcomes of
nterest (Table 2). Hospitalization or ED visits for asthma and pneu-
onia were more frequent among LAIV-vaccinated compared with
IV-vaccinated children (difference in frequency of asthma visits,
.1 [95% CI, −1.9 to 8.0] per 1000; difference in frequency of pneu-
onia visits, 2.4 [95% CI, −2.6 to 7.3] per 1000). The frequency of
ny hospitalization or ED visit was similar among LAIV and TIV
ecipients.
Among the 8308 children aged 24 through 59 months with
sthma or wheezing vaccinated with LAIV and without vaccina-
ion for H1N1 concurrently or during follow-up, there were few
ower respiratory outcomes of interest (Table 3). Hospitalization
r ED visits for each LRI evaluated were not more frequent among (2012) 6099– 6102
LAIV-vaccinated compared with TIV-vaccinated children. The fre-
quency of any hospitalization or ED visit among LAIV recipients did
not show an excess relative to that among TIV recipients.
Of  the 361 LAIV-vaccinated children in cohort 4, 229 (63%) quali-
ﬁed as immunocompromised because of a prescription for systemic
corticosteroids, while 64 (18%) qualiﬁed due to a diagnosis code
for chemotherapy, 55 (15%) qualiﬁed due to congenital immune
deﬁciency, and 8 (2%) qualiﬁed due to a hematologic or lym-
phatic cancer. After excluding 37 (10%) children with a 2009 H1N1
pandemic vaccination, among the remaining 324 LAIV-vaccinated
children with immunocompromise, 14 children experienced an ED
visit for common childhood conditions and injuries; there were no
hospitalizations. Six were associated with primary diagnosis codes
that could be considered infectious diseases (3 for croup and 1
each for pharyngitis, acute respiratory infection, and otitis media),
for a frequency of 18.5 (95% CI, 6.8–39.9) per 1000 vaccinations,
compared with a frequency of 53.8 (95% CI, 43.5–65.8) per 1000
immunocompromised TIV-vaccinated children. The rate of ED vis-
itation or hospitalization among LAIV recipients was  43.2 (95% CI,
23.6–72.5) per 1000 vaccinations, and among TIV-vaccinated chil-
dren was 237 per 1765 vaccinations (134 [95% CI, 118–152] per
1000 vaccinations).
Over the 3 seasons of the entire study period, cumulative LAIV
vaccinations included in the denominators for the annual safety
analyses were 1361 children <24 months, 11,353 children with
asthma or wheezing, and 425 immunocompromised children.
4.  Discussion
As in previous years [2], the low rates of vaccination with LAIV
in cohorts 1, 2, and 4 indicate that healthcare providers in general
are complying with the product labeling. In addition, the rate of
use in recommended and nonrecommended populations contin-
ued to rise at a similar rate to that observed between years 1 and
2, suggesting that clinicians are more often choosing to vaccinate
young children with LAIV. This same increase in the use of LAIV in
children was  observed in another large database of US healthcare
claims data [5].
Continuing the trend observed in the preceding 2 seasons, the
somewhat similar rates of LAIV use in those with recurrent wheez-
ing and in the general population suggest that our deﬁnition of
recurrent wheezing may  not match providers’ deﬁnitions of recur-
rent wheezing and may  have been overly inclusive. We  based
our study deﬁnition of recurrent wheezing, 1 or more dispens-
ings of a short acting beta agonist in the previous 12 months
and the absence of an asthma diagnosis, on the Advisory Com-
mittee on Immunization Practices (ACIP) recommended deﬁnition
of 1 episode of asthma or wheezing in the previous 12 months.
By deﬁnition, recurrent wheezing requires multiple episodes of
wheezing and frequently in the medical literature a deﬁnition of
3 or more episodes is applied over a period of 6–12 months [6–12].
The disparity in these deﬁnitions and the subsequent vaccina-
tion decision-making by clinicians is likely at the root of the less
restricted use of LAIV in this population.
Across the 3 evaluated seasons, the frequency of safety
outcomes was  numerically similar among the LAIV-vaccinated chil-
dren compared with TIV-vaccinated children in all cohorts, except
for among children younger than 24 months in the 2009–2010 sea-
son. Among the small number of children younger than 24 months
who received LAIV compared with those who  received TIV, the
conﬁdence interval around the difference in rates for asthma hospi-
talizations or ED visits was  −1.9 to 8.0 per 1000 vaccinations and for
pneumonia hospitalizations or ED visits was  −2.6 to 7.3 per 1000.
The numbers of events were too small to make deﬁnitive conclu-
sions about the relative frequency of hospitalizations or ED visits for
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Table 1
Vaccination incidence, season 3 (2009–2010).
Cohort Child-days, n LAIV vaccination TIV vaccination
n Incidencea per 10,000
child-days (95% CI)
n Incidence per 10,000
child-days  (95% CI)
Aged <24 months (cohort 1) 70,800,221 775 0.109 (0.102–0.117) 228,875 32.33 (32.19–32.46)
Aged  24–59 months, asthma (cohort 2) 7,804,852 3457 4.43 (4.28–4.58) 26,508 33.96 (33.55–34.37)
Aged  24–59 months, recurrent wheezing (cohort 3) 7,914,091 5821 7.36 (7.17–7.54) 20,228 25.56 (25.21–25.91)
Aged  24–59 months, immunocompromise (cohort 4) 613,883 361 5.88 (5.27–6.49) 2115 34.45 (32.98–35.92)
Aged  24–59 months, general populationb 108,310,074 100,511 9.28 (9.22–9.34) 194,476 17.96 (17.88–18.04)
LAIV: live attenuated inﬂuenza vaccine; TIV: inactivated trivalent inﬂuenza vaccine.
a Codes: G0008, administration of inﬂuenza virus vaccine; V04.81, need for prophylactic vaccination and inoculation against certain diseases: inﬂuenza; V06.6, need for
prophylactic vaccination and inoculation against combinations of diseases: Streptococcus pneumoniae (pneumococcus) and inﬂuenza.
b Children aged 24–59 months in source population.
Table 2
Number of emergency department visits or hospitalizations for lower respiratory conditions among children <24 months of age within 42 days of vaccination, season 3
(2009–2010).
Condition LAIV (n = 686) TIV (n = 190,618)
Events,a n Rateb (95% CI) Events,a n Rateb (95% CI)
Asthma 3 4.4 (0.9–12.7) 245 1.3 (1.1–1.5)
Bronchiolitis  1 1.5 (0.0–8.1) 407 2.1 (1.9–2.4)
Croup  2 2.9 (0.4–10.5) 701 3.7 (3.4–4.0)
Inﬂuenzac 2 2.9  (0.4–10.5) 476 2.5  (2.3–2.7)
Pneumonia  3 4.4 (0.9–12.7) 389 2.0 (1.8–2.3)
Totald 10 14.6 (7.0–26.6) 2153 11.3 (10.8–11.8)
Any  hospitalization or ED visit 40 58.3 (41.7–79.4) 10,807 56.7 (55.6–57.8)
ED: emergency department; LAIV: live attenuated inﬂuenza vaccine; TIV: inactivated trivalent inﬂuenza vaccine.
a An event could be an ED visit or hospitalization.
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Eb Events per 1000 vaccinations.
c With or without pneumonia.
d Numbers of children with each LRI may not be mutually exclusive if a child exp
sthma or pneumonia among LAIV-vaccinated subjects compared
ith TIV-vaccinated subjects. These observations are consistent
ith the increased risk of medically signiﬁcant wheezing previ-
usly seen in children 6 through 23 months of age, which resulted
n LAIV receiving approval for eligible children 24 months of age
nd older [7]. In the results described here and in clinical trials, an
ncreased risk of respiratory events following LAIV has not been
een in children 24 months of age and older.
Among the 3 evaluated nonrecommended cohorts 24 through
9 months of age, no signals for new or unusual conditions during
ollow-up were identiﬁed during the ﬁrst 2 study seasons [2] nor
uring this third and last evaluated season. No excess risk of all-
ause hospitalizations or ED visits was observed among children
ith asthma/wheezing or with immunocompromise who were
accinated with LAIV compared with those vaccinated with TIV.
lthough the risk of some respiratory conditions in children aged
able 3
umber of emergency department visits or hospitalizations for lower respiratory conditio
 (2009–2010).
Condition LAIV (n = 8308) 
Events,a n Rateb (
Asthma 37 4.5 (3
Bronchiolitis  2 0.2 (0
Croup  23 2.8 (1
Inﬂuenzac 23 2.8 (1
Pneumonia  27 3.2 (2
Any  LRId 110 13.2 (1
Any  hospitalization or ED visit 444 53.4 (4
D: emergency department; LAIV: live attenuated inﬂuenza vaccine; LRI: lower respirato
a An event could be an ED visit or hospitalization.
b With or without pneumonia.
c Events per 1000 vaccinations.
d Numbers of children with each LRI may not be mutually exclusive if a child experienced 2 separate diagnoses on separate occasions.
<24  months was  numerically greater among LAIV-vaccinated chil-
dren, the magnitude of this excess was  small and the estimate was
imprecise. However, the cumulative results should be viewed in
light of the available sample sizes. Except for the cohort of children
with asthma and wheezing, the sample sizes of children vaccinated
with LAIV were too small to detect rare events, e.g. occurring at or
less than 1/1000 vaccinations. Over the 3 seasons, LAIV vaccination
was recorded among 1361 children <24 months, 11,353 children
with asthma or wheezing, and 425 immunocompromised children.
These summed sample sizes are sufﬁcient to detect with 95% prob-
ability at least 1 event across all 3 seasons for events that occur at
rates of >2.2 per 1000 among <24-month-old children, >0.26 per
1000 among the 24- through 59-month-old children with asthma
or wheezing, and >7 per 1000 among immunocompromised.
The observational design and lack of randomization or matching
is useful for real world safety surveillance but can easily result in
ns among children with asthma or wheezing within 42 days of vaccination, season
TIV (n = 39,407)
95% CI) Events,a n Rateb (95% CI)
.1–6.1) 373 9.5 (8.5–10.5)
.0–0.9) 29 0.7 (0.5–1.1)
.8–4.2) 144 3.7 (3.1–4.3)
.8–4.2) 150 3.8 (3.2–4.5)
.1–4.7) 139 3.5 (3.0–4.2)
0.9–15.9) 806 20.5 (19.1–21.9)
8.6–58.7) 2657 67.4 (64.9–70.0)
ry tract infection; TIV: inactivated trivalent inﬂuenza vaccine.
ed 2 separate diagnoses on separate occasions.
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omparison of groups with different health status. This imbalance
s likely to have occurred for the comparison of LAIV-vaccinated
hildren with TIV-vaccinated children within each cohort. The con-
istently higher overall frequency of hospitalization and ED visits
bserved among TIV-vaccinated children with asthma and wheez-
ng and among the cohort with immunocompromise suggests that
linicians on average vaccinated the healthiest children in these
opulations with LAIV.
The  limitations of using healthcare claims for such monitor-
ng efforts were discussed in detail in the previous report for
his monitoring effort. Brieﬂy, these issues include potential mis-
lassiﬁcation of outcomes and cohort membership related to use
f claims diagnosis and dispensing codes, rare miscoding of vac-
ine type, and imprecision of children’s age assignment around
he 24-month birthday related to lack of birth date information.
fter 3 years of monitoring, we have not identiﬁed any signif-
cant unexpected safety concerns but acknowledge that some
ample sizes have been too small to evaluate for rare adverse out-
omes associated with LAIV. However, this is entirely appropriate
ecause the sample size indicates that clinicians are not commonly
sing LAIV in pediatric populations not recommended for LAIV
se.
cknowledgements
Contributors: Study concept and design: all authors. Acquisi-
ion of data: Dr. Tennis, Dr. Andrews and Ms.  McQuay. Analysis
nd interpretation of data: all authors. Drafting and revision of the
anuscript: all authors. Statistical analysis: Dr. Tennis, Dr. Andrews
nd Ms.  McQuay. All authors have seen and approved the ﬁnal
anuscript for submission. Financial disclosures: Dr. Tennis, Dr.
ndrews and Ms.  McQuay are employees of RTI Health Solutions,
esearch Triangle Park, NC. Drs. Toback and Ambrose are employ-
es of MedImmune, LLC, Gaithersburg, MD.
Funding/support: This research was sponsored by MedImmune,
LC.
[ (2012) 6099– 6102
Role of the sponsor: Employees of MedImmune worked collabo-
ratively with the investigators of RTI Health Solutions in the design
of the study, in interpretation of the results, and reviewed and
contributed to the manuscript.
Additional contributions: We  would like to thank Complete
Healthcare Communications, Inc. (Chadds Ford, PA, USA) for edi-
torial assistance in manuscript preparation.
References
[1] Belshe RB, Ambrose C, Yi T. Safety and efﬁcacy of live attenuated inﬂuenza
vaccine in children 2–7 years of age. Vaccine 2008;26:D10–6.
[2]  Tennis P, Toback SL, Andrews E, McQuay LJ, Ambrose CS. A postmarketing evalu-
ation of the frequency of use and safety of live attenuated inﬂuenza vaccine use
in nonrecommended children younger than 5 years. Vaccine 2011;29:4947–52.
[3] Rothman K. Epidemiology, an introduction. New York: Oxford University Press;
2002.
[4] Bundy DG. Hospitalizations with primary versus secondary discharge diag-
noses of asthma: implications for pediatric asthma surveillance. J Pediatr
2007;150:446–9, 9 e1.
[5] Toback SL, Herley J, Edelman L, Ambrose CS. Trends in U.S. pediatric inﬂuenza
vaccination from 2006 to 2010 among children with private insurance. Vaccine
2011;29:4225–9.
[6] Esposito S, Marchisio P, Bosis S, Lambertini L, Claut L, Faelli N, et al. Clinical and
economic impact of inﬂuenza vaccination on healthy children aged 2–5 years.
Vaccine 2006;24:629–35.
[7] Belshe RB, Edwards KM,  Vesikari T, Black SV, Walker RE, Hultquist M,  et al. Live
attenuated versus inactivated inﬂuenza vaccine in infants and young children.
N Engl J Med  2007;356:685–96.
[8] Barrueto L, Mallol J, Figueroa L. Beclomethasone dipropionate and salbutamol
by metered dose inhaler in infants and small children with recurrent wheezing.
Pediatr Pulmonol 2002;34:52–7.
[9] Lehtinen P, Ruohola A, Vanto T, Vuorinen T, Ruuskanen O,  Jartti T. Prednisolone
reduces recurrent wheezing after a ﬁrst wheezing episode associated with
rhinovirus infection or eczema. J Allergy Clin Immunol 2007;119:570–5.
10] Lombardi E, Morgan WJ,  Wright AL, Stein RT, Holberg CJ, Martinez FD. Cold air
challenge at age 6 and subsequent incidence of asthma. A longitudinal study.
Am J Respir Crit Care Med  1997;156:1863–9.
11] Sigurs N, Gustafsson PM,  Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F,
et  al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and
allergy at age 13. Am J Respir Crit Care Med 2005;171:137–41.
12]  Teper AM, Kofman CD, Szulman GA, Vidaurreta SM,  Maffey AF. Fluticasone
improves pulmonary function in children under 2 years old with risk factors
for asthma. Am J Respir Crit Care Med  2005;171:587–90.
